AMAG Pharmaceuticals, Inc. Finds Safety Issues With Kidney Drug, Feraheme, Slashes Jobs by 24%

Published: Oct 29, 2010

Oct 28 (Reuters) - AMAG Pharmaceuticals (AMAG.O) found potential safety issues with its key kidney drug Feraheme, which reported declining sales, and said it will cut about a fourth of its workforce, sending the stock crashing 25 percent in extended trade.

Back to news